Eye Gene아이진
185490 · KOSDAQ · ₩185490 · 아이진
₩1,705▼ ₩45 (2.57%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩3.6B | ₩3.4B | ₩3.1B | ₩5.3B | ₩3.2B |
| Cost of sales | ₩2.5B | ₩2.2B | ₩1.2B | ₩2.5B | ₩1.7B |
| Gross profit | ₩1.1B | ₩1.2B | ₩1.9B | ₩2.7B | ₩1.5B |
| Operating income | −₩9.9B | −₩13B | −₩27B | −₩24B | −₩35B |
| Net income | −₩19B | −₩13B | −₩22B | −₩26B | −₩35B |
| Net income to shareholders | −₩16B | −₩12B | −₩22B | −₩26B | −₩35B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩68B | ₩65B | ₩78B | ₩80B | ₩105B |
| Current assets | ₩48B | ₩35B | ₩57B | ₩69B | ₩89B |
| Cash and equivalents | ₩10B | ₩1.4B | ₩5.5B | ₩2B | ₩2.6B |
| Total liabilities | ₩14B | ₩14B | ₩14B | ₩11B | ₩16B |
| Current liabilities | ₩10B | ₩11B | ₩6.1B | ₩4.9B | ₩9.6B |
| Borrowings | ₩3.3B | ₩1.8B | ₩1.5B | ₩1.4B | ₩3B |
| Total equity | ₩54B | ₩51B | ₩64B | ₩69B | ₩89B |
| Shareholders' equity | ₩57B | ₩50B | ₩63B | ₩69B | ₩89B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩6B | −₩12B | −₩20B | −₩19B | −₩30B |
| Capital spending | ₩103M | ₩1.5B | ₩1.4B | — | — |
| Free cash flow | −₩6.1B | −₩14B | −₩21B | −₩19B | −₩30B |
Consolidated where available. Amounts in won.
Also known as: Eye Gene / 아이진 / 185490 / KRX:185490
Source: KRX statistical information